Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
This study does have important limitations to consider The
2022-08-12

This study does have important limitations to consider. The utilization of a recombinant gp120 monomer (at a single concentration of 100 ng/ml) instead of live virus particles may limit the validity of our results. Moreover, extrapolation of an in vitro cell culture model to animals or humans cannot
uncouplers of oxidative phosphorylation br Dysregulation of
2022-08-12

Dysregulation of glutamate transporter expression and function Aberrant glutamate transporter function and expression are associated with various neurological disorders. Therefore, understanding the underlying mechanisms of EAAT1/2 expression may provide therapeutic targets for treating neurologi
Given the actions of GIP analogues administered as
2022-08-12

Given the actions of GIP analogues administered as a single dose to ob/ob mice, studies were performed to assess their ability to act in vivo as antagonists of GIP-induced insulinotropic and antihyperglycaemic actions. (Ala3)GIP, (Phe3)GIP, (Tyr3)GIP and (Pro3)GIP all counteracted the glucose-loweri
No specific inhibitor of KCC has progressed to
2022-08-12

No specific inhibitor of KCC has progressed to clinical trials, however, although compounds like H74 were shown to specifically target KCC over the related Na+-K+-2Cl− cotransporter (NKCC) (Ellory et al., 1990). This molecule, or its related analogues, represent compounds of promise. Simple Mg suppl
A few previous studies have examined Factor Xa inhibitors
2022-08-11

A few previous studies have examined Factor Xa inhibitors for VTE prophylaxis in hip fracture patients. In a 2001 paper, Eriksson et al. studied 1250 patients with hip fractures that had been randomized to either postoperative Factor Xa inhibitor or enoxaparin [13]. Each patient received bilateral v
Our observation of LPS induced
2022-08-11

Our observation of LPS-induced increase in the sensitivity of cultured endothelium-intact coronary (S)-(+)-Dimethindene maleate towards stimulation with selective ETB receptor agonist (S6c) could be explained by activation of TLRs receptors located on the endothelium of rat coronary arteries. Howev
Consideration must be given to both
2022-08-11

Consideration must be given to both the tissues themselves and to infiltrating immune cells. As highlighted by Maxwell and Eckardt [88], clinical trials of compounds targeting these pathways will require large numbers of participants and prolonged follow-up to identify rare and late complications or
Spindle positioning is governed by the actin cytoskeleton
2022-08-11

Spindle positioning is governed by the actin cytoskeleton. After a transient metaphase arrest, cells lacking haspin exhibit a misdistribution of actin, which accumulates within the bud. Actin dynamics is modulated by an intricate network including septins, the polarisome complex, and formins. We sho
5 03 br GSK The GSK family is highly conserved
2022-08-11

GSK-3 The GSK-3 family is highly conserved throughout evolution and is encoded by two genes, GSK-3α and GSK-3β, which are located in chromosomes 19q13.2 and 3q13.3 in human, respectively. Both GSK-3α and GSK-3β proteins exist in a variety of tissues with the highest levels found in 5 03 [1], [2]
GPR and TRPV co localized in
2022-08-11

GPR35 and TRPV1 co-localized in small- and medium-diameter DRG neurons. Nociceptive (Aδ- and C-fiber) neurons expressing TRPV1 mediate hyperalgesia, neurogenic inflammation, and neuropathic pain [12]. The cAMP-protein kinase A (PKA) dependent modifications of TRPV1 currents have been demonstrated in
br Synthetic Antagonists for FFA To date only compounds from
2022-08-11

Synthetic Antagonists for FFA4 To date, only compounds from a single chemical series have been reported as FFA4 ‘antagonists’ (Table 1). ‘Compound 39’ (4-methyl-N-9H-xanthen-9-yl-benzenesulfonamide), now available from commercial vendors as AH-7614, was initially reported as an antagonist at this
Acute in vivo experiments were performed in normoglycemic SV
2022-08-11

Acute in vivo experiments were performed in normoglycemic 129SVE mice to confirm GPR119 activation and corresponding glycogen phosphorylase control. GIP release was utilized as a biomarker for target receptor engagement and plasma GIP levels were measured 45min after oral dosing (). Both 3 and 10mg
The use of HIV peptide epitope based vaccines is
2022-08-11

The use of HIV-1 peptide epitope-based vaccines is safer and cheaper than live or inactivated vaccines [8]. However, peptide epitope vaccines could show poor immunogenicity and have poor uptake by APCs [9]. Nevertheless, nanocarrier-based delivery platforms have been demonstrated to enhance the pept
Neurotransmitter transporters are rapidly recycled from and
2022-08-11

Neurotransmitter transporters are rapidly recycled from and to the membrane. For instance, the GABA transporter GAT1 is recycled in a calcium and depolarization dependent manner. GAT1 located in the plasma membrane is internalized to a subpopulation of small vesicles different from the classical neu
br Results br Discussion We have
2022-08-11

Results Discussion We have reported the crystal structures of VcmN, the high-resolution structures of this MATE transporter from a pathogenic bacterium. The structures display distinct conformations of TM1, as a consequence of their unique hydrogen-bonding networks. We interpret this result to
8103 records 414/541 page Previous Next First page 上5页 411412413414415 下5页 Last page